Yan Jiang1, Oliver Lin1, Sidhartha R Sinha2. 1. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 300 Pasteur Dr., Alway Building M211, Stanford, CA, 94305, USA. 2. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 300 Pasteur Dr., Alway Building M211, Stanford, CA, 94305, USA. sidsinha@stanford.edu.
Abstract
BACKGROUND: Prescribing information for tumor necrosis factor alpha (TNFα) inhibitors, a mainstay of treatment for moderate to severe inflammatory bowel disease (IBD), instructs cautious use in those with heart failure (HF). However, the limited data behind these warnings are inconclusive and should be weighed against mounting evidence demonstrating worse cardiac outcomes in active IBD. AIMS: To assess whether TNFα inhibitor use is reduced in patients with IBD and HF by analyzing physician practice and prescription patterns. METHODS: Using a Stanford University database, we queried TNFα inhibitor prescriptions in 8905 patients with an ICD-9 diagnosis of Crohn's disease or ulcerative colitis. Detailed chart review analysis was done for patients with a concurrent diagnosis of HF who were prescribed anti-TNFα agents. In addition, we collected survey data from 25 gastroenterologists on their usage of these drugs for patients with IBD and HF. RESULTS: TNFα inhibitors were prescribed to 10/455 (2.2%) IBD patients with HF compared to 1265/8450 (15.0%) in IBD patients without HF (p < 0.0001). Of those ten with HF prescribed TNFα inhibitors, only one had it discontinued because of HF exacerbation while on drug. Survey data indicated few (5/25) providers do not actively avoid TNFα inhibitors for those with HF. CONCLUSIONS: IBD patients with HF are prescribed significantly less TNFα inhibitors than those without HF. The majority of providers are either uncertain about or actively avoid use of anti-TNFα medications for those with HF. The risks and benefits of anti-TNFα use in HF patients must be investigated further.
BACKGROUND: Prescribing information for tumor necrosis factor alpha (TNFα) inhibitors, a mainstay of treatment for moderate to severe inflammatory bowel disease (IBD), instructs cautious use in those with heart failure (HF). However, the limited data behind these warnings are inconclusive and should be weighed against mounting evidence demonstrating worse cardiac outcomes in active IBD. AIMS: To assess whether TNFα inhibitor use is reduced in patients with IBD and HF by analyzing physician practice and prescription patterns. METHODS: Using a Stanford University database, we queried TNFα inhibitor prescriptions in 8905 patients with an ICD-9 diagnosis of Crohn's disease or ulcerative colitis. Detailed chart review analysis was done for patients with a concurrent diagnosis of HF who were prescribed anti-TNFα agents. In addition, we collected survey data from 25 gastroenterologists on their usage of these drugs for patients with IBD and HF. RESULTS: TNFα inhibitors were prescribed to 10/455 (2.2%) IBDpatients with HF compared to 1265/8450 (15.0%) in IBDpatients without HF (p < 0.0001). Of those ten with HF prescribed TNFα inhibitors, only one had it discontinued because of HF exacerbation while on drug. Survey data indicated few (5/25) providers do not actively avoid TNFα inhibitors for those with HF. CONCLUSIONS:IBDpatients with HF are prescribed significantly less TNFα inhibitors than those without HF. The majority of providers are either uncertain about or actively avoid use of anti-TNFα medications for those with HF. The risks and benefits of anti-TNFα use in HF patients must be investigated further.
Authors: W Miehsler; G Novacek; H Wenzl; H Vogelsang; P Knoflach; A Kaser; C Dejaco; W Petritsch; M Kapitan; H Maier; W Graninger; H Tilg; W Reinisch Journal: J Crohns Colitis Date: 2010-03-17 Impact factor: 9.071
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald Journal: Gastroenterology Date: 1994-06 Impact factor: 22.682
Authors: Richard A Hansen; Gerald Gartlehner; Gregory E Powell; Robert S Sandler Journal: Clin Gastroenterol Hepatol Date: 2007-05-04 Impact factor: 11.382
Authors: Patricia P Chang; Lloyd E Chambless; Eyal Shahar; Alain G Bertoni; Stuart D Russell; Hanyu Ni; Max He; Thomas H Mosley; Lynne E Wagenknecht; Tandaw E Samdarshi; Lisa M Wruck; Wayne D Rosamond Journal: Am J Cardiol Date: 2013-11-09 Impact factor: 2.778
Authors: Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming Journal: Circulation Date: 2004-03-15 Impact factor: 29.690